Skip to main content

MapLight Therapeutics, Inc.

For the period ended Mar 31, 2026. Filed May 14, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 14, 2026

MPLT$7.28+5.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

March 31,December 31,
20262025
Assets
Current assets:
Cash and cash equivalents$55,707$46,729
Short-term investments254,406258,374
Prepaid expenses and other current assets17,11519,567
Total current assets327,228324,670
Property and equipment, net9681,095
Long-term investments85,090147,993
Restricted cash207207
Right-of-use asset5,2595,488
Other assets3659
Total assets$418,788$479,512
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable$3,188$3,289
Accrued expenses10,17512,049
Lease liability - current920891
Total current liabilities14,28316,229
Lease liability - noncurrent4,6714,911
Total liabilities18,95421,140
Commitments and contingencies (Note 11)
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025——
Common stock, $0.0001 par value per share; 500,000,000 shares authorized at March 31, 2026 and December 31, 2025; 45,208,922 and 44,024,088 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively55
Additional paid-in-capital821,900819,115
Accumulated other comprehensive loss(883)(228)
Accumulated deficit(421,188)(360,520)
Total stockholders' equity399,834458,372
Total liabilities and stockholders' equity$418,788$479,512
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.